Siglec Signaling in the Tumor Microenvironment

Area of Science:

• Immunology
• Glycobiology
• Cancer Biology

Background:

• Sialic acid-binding immunoglobulin-like lectins (Siglecs) are immune cell receptors recognizing sialoglycans.
• Siglecs possess immune inhibitory motifs, similar to PD-1, and are implicated in tumor immune evasion.
• Both Siglec expression on immune cells and sialoglycan ligands on tumor cells are often upregulated in the tumor microenvironment.

Purpose of the Study:

• To review the current understanding of Siglec signaling in the tumor microenvironment (TME).
• To identify key factors regulating Siglec activation by tumor-associated sialoglycans.
• To highlight existing knowledge gaps in the field of Siglec-mediated tumor immunity.

Main Methods:

• Literature review of Siglec function and signaling in cancer.
• Analysis of mechanisms promoting Siglec-sialoglycan axis activation in the TME.
• Synthesis of factors influencing Siglec-ligand interactions and downstream signaling.

Main Results:

• The Siglec-sialoglycan axis contributes to tumor immune evasion, mirroring PD-1/PD-L1 pathways.
• Siglec activation is influenced by receptor expression, localization, and binding preferences for cis- and trans-ligands.
• Tumor-associated sialoglycans, altered by aberrant glycosylation, enhance Siglec engagement.

Conclusions:

• Siglec signaling is a critical regulator of anti-tumor immunity, but the precise mechanisms are complex and not fully defined.
• Factors like ligand presentation, protein/lipid attachment, and interaction multivalency significantly impact Siglec activity.
• Further research is needed to elucidate the diverse factors governing Siglec signaling for effective cancer immunotherapy development.